| Trial ID: | L0286 |
| Source ID: | NCT00706537
|
| Associated Drug: |
CP-945598
|
| Title: |
Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-Alcoholic Steatohepatitis(NASH)
|
| Interventions: |
Drug: Active treatment|Drug: Placebo
|
| Outcome Measures: |
Urine 6-??-hydroxycortisol:cortisol ratio|Adverse event monitoring, physical examinations, sitting vital sign measurements (blood pressure and pulse rate), 12-lead ECGs, laboratory safety assessments.|PK for CP-945598 and its primary circulating metabolite|Breath ID?? tests (methacetin and octanoate)|Soluble and exploratory biomarkers
|
| Sponsor/Collaborators: |
Pfizer
|
| Gender: |
All
|
| Age: |
18 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
9
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science
|
| Start Date: |
July 2008
|
| Completion Date: |
November 2008
|
| Results First Posted: |
--
|
| Last Update Posted: |
August 13, 2009
|
| Locations: |
Pfizer Investigational Site, Anaheim, California, United States|Pfizer Investigational Site, Anaheim, California, United States|Pfizer Investigational Site, Durham, North Carolina, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT00706537
|
